Skip to main content

Market Overview

12 Biggest Mid-Day Losers For Monday

Share:

 

  • Dynavax Technologies Corporation (NASDAQ: DVAX) shares tumbled 64.9 percent to $4.07 after the disclosure of a Complete Response Letter (CRL) from the FDA on its Biologics License Application for HEPLISAV-B. The drug candidate is meant for immunization of adults 18 years and older affected by hepatitis B infection.
  • Resource Capital Corp. (NYSE: RSO) shares declined 27.7 percent to $8.80. Resource Capital reported Q3 funds from operations of $12.9 million, or $42 per share.
  • Puma Biotechnology Inc (NYSE: PBYI) shares fell 22.3 percent to $39.15 on Friday's KSF investigation into the company.
  • Turtle Beach Corp (NASDAQ: HEAR) dropped 21.2 percent to $1.52. B. Riley downgraded Turtle Beach from Buy to Neutral.
  • JetPay Corporation (NASDAQ: JTPY) declined 15.1 percent to $2.25. JetPay reported a Q3 loss of $0.16 per share on revenue of $15.21 million.
  • Net Element International Inc (NASDAQ: NETE) shares fell 13.7 percent to $0.950. Net Element reported Q3 adjusted loss of $0.20 per share on revenue of $14.01 million.
  • Patriot National Inc (NYSE: PN) declined 13.2 percent to $5.94. Patriot National posted Q3 earnings of $0.12 per share on revenue of $60.2 million.
  • Galena Biopharma Inc (NASDAQ: GALE) dropped 12.4 percent to $3.68 after the company disclosed that data from GALE-301/GALE-302 clinical program was presented at the Society for Immunotherapy of Cancer Conference 2016.
  • NetSol Technologies Inc. (NASDAQ: NTWK) fell 12.2 percent to $5.40. NETSOL posted a Q1 loss of $0.17 per share on revenue of $15 million.
  • Gold Standard Ventures Corp (NYSE: GSV) shares declined 11.2 percent to $1.91. Gold Standard Ventures shares have jumped 298.15 percent over the past 52 weeks, while the S&P 500 index has gained 5.42 percent in the same period.
  • Edgewater Technology Inc. (NASDAQ: EDGW) dropped 10.4 percent to $7.17 as the company reported the conclusion of formal review of strategic alternatives.
  • Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) declined 3.7 percent to $79.03. Citigroup downgraded Ultragenyx Pharmaceutical from Neutral to Sell.
 

Related Articles (DVAX + RSO)

View Comments and Join the Discussion!

Posted-In: Mid-Day LosersNews Movers & Shakers Intraday Update Markets

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com